L-Lysine
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | L-Lysine |
| DrugBank ID | DB00123 |
| Brand Names (EU) | L-Lysine |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.77% |
Approved Indication (EMA)
See EMA product information
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | gastroparesis (disease) | 99.77% | DL |
| 2 | congenital prothrombin deficiency | 99.13% | DL |
| 3 | obsolete vitamin D deficiency | 99.02% | DL |
| 4 | dyspepsia | 98.68% | DL |
| 5 | familial visceral myopathy | 98.37% | DL |
| 6 | vitamin deficiency disorder | 98.21% | DL |
| 7 | hypophosphatemic rickets | 97.98% | DL |
| 8 | renal tubular acidosis | 97.80% | DL |
| 9 | biotin metabolic disease | 97.80% | DL |
| 10 | postgastrectomy syndrome | 97.30% | DL |
| 11 | albinism-deafness syndrome | 97.15% | DL |
| 12 | postmenopausal osteoporosis | 96.99% | DL |
| 13 | intestinal obstruction | 96.96% | DL |
| 14 | myopathic intestinal pseudoobstruction | 96.67% | DL |
| 15 | unclassified intestinal pseudoobstruction | 96.67% | DL |
| 16 | stomach disease | 96.66% | DL |
| 17 | neuronal intestinal dysplasia, type B | 96.53% | DL |
| 18 | acne (disease) | 96.49% | DL |
| 19 | familial isolated hypoparathyroidism due to impaired PTH secretion | 96.19% | DL |
| 20 | hereditary hypophosphatemic rickets | 95.88% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.